The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1144
November 25, 2002
View Complete Issue         Table of Contents 2019 
Ibritumomab Tiuxetan (Zevalin) for Non-Hodgkin's Lymphoma
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Ibritumomab Tiuxetan (Zevalin) for Non-Hodgkin's Lymphoma
November 25, 2002 (Issue: 1144)
Yttrium-90 ibritumomab tiuxetan (Zevalin -IDEC) was approved by the FDA for treatment of patients with relapsed or refractory low-grade follicular or transformed B-cell non-Hodgkin's lymphoma (NHL), including patients with follicular lymphoma...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Ibritumomab Tiuxetan (Zevalin) for Non-Hodgkin's Lymphoma
Article code: 1144c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.